Interleukin-1 alpha increases the cytotoxic activity of etoposide against human osteosarcoma cells.
The recurrence of pulmonary metastases resistant to salvage chemotherapy continues to be a major problem in osteosarcoma patients. Our goal is to identify novel combinations of biologic response modifiers plus chemotherapeutic agents that can be translated into clinical trials. Response rates of relapsed osteosarcoma patients to etoposide have been extremely low. The present investigation demonstrated that IL-1 alpha dramatically increased the sensitivity of MG-63, SAOS-2, and TE-85 osteosarcoma cells to etoposide when the two agents were used simultaneously. The cytostatic activity of 1 microM etoposide was increased from 35 to 70%, 30 to 65%, and 4 to 90%, respectively, by 5.0 U/ml IL-1 alpha. Analysis using the colony-forming assay to quantify cytotoxicity showed that the percentage of cell survival following exposure to etoposide decreased from 0.81 to 0.56, 0.55 to 0.2, and 0.4 to 0.05 when the combination treatment was used. Increased sensitivity was not seen when etoposide treatment preceded IL-1 alpha treatment. IL-1 alpha also increased the sensitivity of these cells to doxorubicin but not to cisplatin or topotecan. The mechanism of this enhanced activity is independent of p-glycoprotein, drug-uptake, or effects on topoisomerase II.
Jia
Shu-Fang
SF
Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Zwelling
Leonard A
LA
McWatters
Amanda
A
An
Taeha
T
Kleinerman
Eugene S
ES
D004250:DNA Topoisomerases, Type II / Q000187:drug effects; D004357:Drug Synergism; D005047:Etoposide / Q000494:pharmacology*; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology*; D012516:Osteosarcoma / Q000188:drug therapy* / Q000473:pathology; D014407:Tumor Cells, Cultured
D007375:Interleukin-1; D005047:Etoposide; D004250:DNA Topoisomerases, Type II